



<https://doi.org/10.47430/ujmr.2271.002>



Received: 20<sup>th</sup> Jan, 2022

Accepted: 24<sup>th</sup> Feb, 2022

## Prevalence of *Plasmodium falciparum* Infection among HIV Patients Attending Selected Hospitals in Niger State, Nigeria

\*<sup>1</sup>Muhammad T. H., <sup>1</sup>Inabo, H. I., <sup>1</sup>Machido, D. A. and <sup>1</sup>Ameh, J.B.

Department of Microbiology, Ahmadu Bello University, Zaria

<sup>1</sup>Department of Microbiology, Faculty of Life Sciences, Ahmadu Bello University, Zaria

\*Corresponding author: ahammad72@gmail.com+2348036860074

### Abstract

*Malaria and Acquired Immune Deficiency Syndrome (AIDS) are among the world's greatest health problems and are concentrated in the tropical and sub-tropical regions of the world. Together, they are the cause of death of millions of people each year, hence they become a burden and a threat for development in India, Southern Asia, South America and Africa including Nigeria. The prevalence of malaria among HIV patients attending selected hospitals in Niger State, Nigeria was determined. A total of 300 HIV patients within the age range of 2-69years were enrolled, of which 217 were females and 83 were males. Four (4) mL of venous blood was drawn from each participant. The blood samples were examined for the presence of Plasmodium falciparum using thin and thick films while the CD<sub>4</sub> count was determined using flow cytometer (Partec Cyflow). Plasmodium falciparum was detected in 43 out of 300 participants with a prevalence of 14.3%. The prevalence was observed to be higher in males (18.07%) than in females (12.90%) and in the age group 1-10years (28.57%). Statistically, there was no association between Plasmodium falciparum infection with sex (p = 0.223) or age (p = 0.253). The CD<sub>4</sub> counts of all the participants ranges between 28-2000 cells/μL with a mean of 1111.40 ± 739.589. Patients with Plasmodium falciparum infection had lower CD<sub>4</sub> counts than those that were negative. Conclusively, HIV individuals with severe immunosuppression (CD<sub>4</sub> counts <200 cells/μL) are at higher risk of Plasmodium falciparum infection. Hence, HIV individuals should take all necessary measures to prevent the infection to avoid the negative impact.*

**Keywords:** *Plasmodium falciparum, anaemia, HIV, malaria, CD<sub>4</sub>, Niger State.*

### INTRODUCTION

Malaria is a parasitic disease caused by five *Plasmodium* species in humans namely *Plasmodium falciparum* (*P. falciparum*), *P. ovale*, *P. malariae*, *P. vivax* and *P. knowlesi*. *Plasmodium falciparum* is the most virulent, predominant species and one of the leading causes of morbidity and mortality in the developing countries. It is estimated that 50% of the world's population are at varying degrees of risk of the *plasmodium falciparum* infection (Adeoti *et al.*, 2015). Acquired Immune Deficiency Syndrome is caused by Human Immunodeficiency Virus (HIV). This virus is also an intracellular pathogen which mostly attacks immune cells of the body such as Clusters of Differentiation at position four (CD<sub>4</sub>) cells and macrophages. It depletes these cells thereby putting the patients at risk of opportunistic infections and malignancy (Berg *et al.*, 2014; WHO, 2020).

These two deadly diseases, Malaria and AIDS, are among the world's greatest health problems and are concentrated in the tropical and sub-tropical regions of the world (WHO, 2017). In

2018, World Health Organization (WHO) approximated the clinical cases of malaria to 228 million with deaths of 405,000 individuals worldwide. About 90% of these cases occur in sub Saharan Africa (SSA) (WHO, 2019). The same year, 37.9 million cases of HIV, 770,000 deaths and 1.7 million new cases were recorded worldwide in which sub Saharan Africa and Nigeria accounts for 61% and 13% of the cases respectively (UNAIDS, 2018).

The co-infection of *Plasmodium falciparum* and HIV may result in quick progression and severity of both diseases in developing nations due to overlap in the geographical distribution. Malaria in HIV patients leads to an increase in viral load and decline in CD<sub>4</sub>/CD<sub>8</sub> counts and function thereby causing severe changes in the immune system (Dada, 2015), resulting to faster disease progression from HIV to AIDS (Kwenti, 2018). HIV, on the other hand can increase the risk and severity of *Plasmodium falciparum* infection and parasite burden which may facilitate high rate of malaria transmission and increased risk of congenital infection (Ouedraogo *et al.*, 2015).

HIV infection can also impair the efficacy of antimalarial treatment, increase adverse events, and select for parasites with drug-resistant mutations due to re-infection with new malaria strains, rather than recrudescence of prior infection (Kanya *et al.*, 2006). Although the prevalence of co-infection between *Plasmodium falciparum* and HIV had been reported in some parts of Nigeria, there are limited reports of these co-infection in Niger State, Nigeria. This study was therefore conducted to determine the prevalence of *Plasmodium falciparum* infection and its effect on CD<sub>4</sub> count in HIV patients attending selected Hospitals in Niger State, Nigeria.

## MATERIALS AND METHODS

### Study Area

This study was conducted in three selected hospitals in Niger State, Nigeria namely: General Hospital Bida, General Hospital Minna and General Hospital New Bussa. Niger State is divided into three senatorial zones namely Zone A (Niger South), Zone B (Niger East) and Zone C (Niger North) hence one hospital was selected from each zone.

### Study Design

This was a hospital-based cross-sectional study involving consenting HIV positive individuals attending General Hospitals Bida, General Hospital Minna and General Hospital New Bussa in Niger State, Nigeria.

### Ethical Approval

Ethical approval was obtained from the Ethical committee of Niger State Hospital Management Board/General Hospital, Minna, Niger State (HMB/GHM/136/VOL.III/590). Consent of participants or guardians of the children was also obtained prior to collection of samples.

### Blood Sample Collection and Processing

Using sterile vacutainer needle/holder, 4mL of blood samples were drawn aseptically by venipuncture from the patients and transferred into a sterile Ethylene Diamine Tetra Acetate (EDTA) anticoagulant bottle. The samples were mixed immediately using vortex mixer (Cheesbrough, 2009).

### Detection of Malaria Parasites

#### Thin and Thick Blood Film

From each participant's blood sample, 2 $\mu$ L of blood was placed on a labelled clean, grease-free glass slide and spread immediately using a smooth-edged slide spreader to make a thin film, as for thick smear, 6 $\mu$ L of blood was used. The slides were allowed to air dry and the thin smears were fixed with methanol. The slides were then flooded with 3% Giemsa working solution (pH 7.2) for 60minutes, washed and

allowed to air dry. The stained blood films were viewed under x100 oil immersion objective lens. A total of 200 fields per film were examined (Cheesbrough, 2009; WHO, 2015).

### Determination of CD<sub>4</sub>Count

The CD<sub>4</sub> count was determined using a two-color single platform flow cytometer (Partec Cyflow) within 6hours of sample collection. Twenty microliter (20 $\mu$ L) CD<sub>4</sub> phycoerythrin (PE) antibody was dispensed into labelled Partec (Rohren) tubes and 20 $\mu$ L of well mixed whole blood was added, mixed with a vortex mixer and incubated in the dark for 15minutes at room temperature. The mixture was mixed at 5minutes interval during incubation. After incubation, 800 $\mu$ L of CD<sub>4</sub> diluting buffer was added to the mixture of antibody and samples mixed gently before analyzing (Cyflow Partec, 2010).

### Data Analysis

All the data collected were entered into Microsoft Excel files and analyzed using STATA statistics/ Data analysis. Univariate analysis which includes descriptive statistics such as percentages and exploration of the distribution of all variables (age, sex, malaria parasite and CD<sub>4</sub> count) was performed. Pearson's correlation co-efficient was used to test the association between categorized variables. The mean values of the parameters were tested using simple linear regression analysis. All tests were performed at 95% confidence interval ( $P \geq 0.05$ ).

## RESULTS

The overall prevalence of *Plasmodium falciparum* is illustrated in Figure 1. A prevalence of 14.3% (43/300) was obtained. Of the 300 HIV patients enrolled in the study, 217 (72.3%) of them were females. The age of the participants ranges between 2-69years. The prevalence of *Plasmodium falciparum* infection among the participants who were enrolled in the study based on age and sex is presented in Table 1. The result obtained revealed variations in the prevalence of *Plasmodium falciparum* infection in all the age groups studied. The age group 1-10years had the highest prevalence of 28.57% while the least prevalence of 9.10% was observed in the age group 41-50years. The findings also revealed a prevalence of 18.07% among males (15/83) while that of females was 12.90% (28/217). There was no statistically significant association between the prevalence of *Plasmodium falciparum* infection with the age and sex of the participants ( $p > 0.05$ ).

Table 2 shows the result of categorized CD<sub>4</sub> count and the occurrence of *Plasmodium falciparum* among the study participants. Participants with CD<sub>4</sub> count <200cells/μL had a higher prevalence (38.9%) of *Plasmodium falciparum* infection. Majority of the HIV

positive patients co-infected with *Plasmodium falciparum* had CD<sub>4</sub> count <200cells/μL followed by those with CD<sub>4</sub> count >500cells/ μL. The association between categorized CD<sub>4</sub> count and distribution of *Plasmodium falciparum* is statistically significant (P < 0.05).




Figure 1: Prevalence of *Plasmodium falciparum* infection among study participants attending selected Hospitals in Niger State, Nigeria

Table 1: Prevalence of *Plasmodium falciparum* infection among the HIV patients based on Age and Sex

Variable	Number examined	Prevalence (%)	x <sup>2</sup>	df	P-value
<b>Age group (Yrs)</b>					
1 - 10	14	4 (28.57)	6.967	5	0.223
11 - 20	19	3 (15.79)			
21 - 30	64	12 (18.75)			
31 - 40	109	12 (11.01)			
41 - 50	66	6 (9.10)			
>50	28	6 (21.43)			
<b>Sex</b>					
Males	83	15 (18.07)	1.306	1	0.253
Females	217	28 (12.90)			

Key: x<sup>2</sup> = Chi-square, df = Degree of freedom, Yrs.= Years.

Table 2: Occurrence of *Plasmodium falciparum* and CD<sub>4</sub>Count among the Study Participants

PF	CD <sub>4</sub> Counts (cells /μL)			df	x <sup>2</sup>	P - value
	1 - 199 No. (%)	200 - 500 No. (%)	>500 No. (%)			
PF Pos	21 (38.9)	7 (12.7)	15 (7.9)	2	33.165	0.000
PF Neg	33 (61.1)	48 (87.3)	176 (92.1)			
Total	54 (100.0)	55 (100.0)	191 (100.0)			

Key: PF - *Plasmodium falciparum*, Pos - Positive, Neg - Negative, df - Degree of freedom.

### DISCUSSION

Malaria is known to cause an increase in transitory viral load while HIV causes more clinical malaria and increases the severity of malaria (Abu-Raddad *et al.*, 2006; Tay *et al.*, 2015). The overall prevalence of *Plasmodium falciparum* infection among HIV patients in this study was 14.3%. The prevalence (14.3%)

obtained in this study may be due to the period of study (dry season) which coincides with low malaria parasite transmission in the north-central parts of Nigeria (Nmadu *et al.*, 2015). It could also be due to the number of participants that were enrolled, frequency of exposure to malaria parasite infection, as well as care seeking attitude of the people living with HIV.

This prevalence is similar to 14.2% reported by Amadi *et al.* (2018) in University of Uyo, Nigeria and 15.5% reported by Tagoe and Boachie (2012) in Ghana. The prevalence obtained in this finding is however lower than 59.2% reported by Abioye *et al.* (2014) in Kaduna, Nigeria and 33.0% reported by Gennaro *et al.* (2018) in Mozambique.

The prevalence of *Plasmodium falciparum* infection (14.3%) in this study is higher than 4.8% reported by Dada (2015) in Ondo State, Nigeria. The finding from this study is also in variance with the prevalence of 7.3% reported by Njunda *et al.* (2016) in Cameroon which was attributed to health-seeking attitude of the HIV patients and use of cotrimoxazole (CTX) based chemoprophylaxis which is recommended for the protection against opportunistic infection in all people living with HIV in Cameroon.

The prevalence of *Plasmodium falciparum* infection among HIV patients in relation to age groups revealed that the highest prevalence of 28.57% was observed among patients within the age group of 1-10 years. This highest prevalence observed may be as a result of their low immunity which makes them susceptible to malaria. The result of this research is in conformity with those of Onankpa *et al.* (2017) who reported high prevalence of *Plasmodium falciparum* infection in HIV children (6-10 years). It is however at variance with the findings of Okonko *et al.* (2012) in Ibadan and Ahmed *et al.* (2016) in Abuja that reported lower prevalence in HIV children.

In this study, males had relatively higher prevalence of *Plasmodium falciparum* infection (18.07%) than their female counterparts (12.90%). This may be attributed to their occupation and travel routines that expose them to higher risk of being bitten by mosquito than HIV positive women. This finding is in conformity with the previous studies of Iroezindu *et al.* (2012) in Jos, Nigeria and Hwida *et al.* (2019) in Sudan who recorded high prevalence of *Plasmodium falciparum* infection in males. However, this finding is in contrast with that of Abioye *et al.* (2014) in Kaduna, Nigeria who reported that HIV positive females were at higher risk of contracting malaria

## REFERENCES

Abioye, J. O. K., Abdullahi, D. K. and Ako, A. A. (2014). Prevalence of Malaria among HIV patients in 44 Nigeria Army reference hospital Kaduna (44NARHK). *International Journal of Advanced Biological Research*. 4(4): 412-415.

compared to their HIV positive male counterparts. There was no statistically significant association between co-infection of *P. falciparum*/HIV with age and sex.

CD<sub>4</sub> counts are used as a measure of HIV infection progression and counts less than 200 cells/ $\mu$ L increases the risk of opportunistic infections. This statement is further supported by an important finding in our study that revealed higher prevalence of *Plasmodium falciparum* infection among HIV patients that have CD<sub>4</sub> count less than 200 cells/ $\mu$ L. This may also be attributed to the weakening of the immune response of the patients which causes decrease in CD<sub>4</sub> count and also exposes them to manifestation of malaria disease (CDC, 2009). This finding is in agreement with the findings of Jegede *et al.* (2017) in Kano, Nigeria and Bouyou-Akotet *et al.* (2018) in Central Africa that recorded high prevalence of malaria in HIV patients with low CD<sub>4</sub> count below 200 cells/ $\mu$ L.

## CONCLUSION

A prevalence (14.3) of *Plasmodium falciparum* infection was observed among HIV positive participants in Niger State, Nigeria. The prevalence was not associated with age or sex ( $p > 0.05$ ). Higher prevalence of *Plasmodium falciparum* infection was obtained in participants with CD<sub>4</sub> count below 200 cells/ $\mu$ L and a negative correlation between the *Plasmodium* parasitaemia and the CD<sub>4</sub> count is indicative of the role of the immune response in the protection against malaria in the target population.

## RECOMMENDATIONS

Routine screening and treatment of malaria in HIV individuals should be adopted as part of the management policy to check the co-infection. Also, health education on malaria transmission and prevention methods should be provided.

## ACKNOWLEDGEMENT

The authors would like to appreciate the ethical committee of NSHMB/GH Minna, Niger State, the clinical and laboratory staff of the HIV clinic as well as the individuals who consented to participate in this study.

Abu-Raddad, L. J., Patnaik, P., Kublin, J. G. (2006) Dual infection with HIV and malaria fuels the spread of both diseases in sub-Saharan Africa. *Science*. 314(5805): 1603-1606.

Adeoti, O. M. I., Awobode, H. O. and Anumudu, C. I. (2015). Cellular Immune Responses to HIV and falciparum



- malaria Co-infection among Pregnant Mothers. *American Journal of Biomedical Research*. 3(2): 13-20.
- Ahmed, P., Oniyangi, O., Oyesakin, A., Adeoye, A., Ulonnam, C. and Mohammed-Nafi'u, R. (2016). Prevalence of Malaria in Paediatric HIV Patients as seen at the National Hospital Abuja Paediatric Association of Nigeria Kaduna, Nigeria. *African Journal of Infectious Disease*. 14(1): 24-32.
- Amadi, C. P., Ikon, G. M. and Inyang, C. (2018). Current prevalence of falciparum malarial infection among HIV patients on Highly Retroviral Therapy in university of Uyo teaching hospital, Uyo Nigeria. *International Journal of Research in Medical Sciences*. 6(9): 2916-2922.
- Berg, A., Patel, S., Aukrust, P., David, C., Gonca, M., Berg, E. S., Dalen, I and Langeland, N. (2014). Increased severity and mortality in adults co-infected with Malaria and HIV in Maputo, Mozambique: a prospective cross-sectional study. *PLoS One*. 9(12): 1 - 16.
- Bouyou-Akotet, M. K., Koumba-Lengongo, J. V., Ondounda M., Kendjoa, E., Delisb, A. M., Mebalea, M. E., Ngomoa, J. M. N., Bondoukwea, N. P. M, Mawili-Mboumbaa, D. P. and Nkoumoub, M. O. (2018). Burden of a symptomatic malaria, anemia and relationship with cotrimoxazole use and CD<sub>4</sub> cell count among HIV1infected adults living in Gabon, Central Africa. *Pathogens and Global Health*, 112(2): 63-71.
- Center for Disease Control and Prevention (CDC) (2009). World Malaria Report 2009. Retrieved from [http://www.cdc.gov/malaria/featurews/world\\_malaria\\_report\\_2009.html](http://www.cdc.gov/malaria/featurews/world_malaria_report_2009.html).
- Cheesbrough, M. (2009). *District Laboratory Practice in Tropical countries (Part 1)*. Cambridge Second Edition. New York: Cambridge University Press, London, 253-328.
- Cyflow Partec (2010) Manual UISOP. CyFlow space. Instrument Equipment Manual. 2010.
- Dada, E. O. (2015). Prevalence of Malaria and Co-infection with Human Immuno-Deficiency Virus (HIV) in selected Areas of Ondo State, Nigeria. *International Journal of Tropical Disease and Health*. 8(1): 34-39.
- Gennaro, F. D., Marotta, C., Pizzol, D., Chhaganlal, K., Monno, L., Putoto, G., Saracino, A., Cascio, A. and Mazzucco, W. (2018). Prevalence and predictors of malaria in human immunodeficiency virus infected patients in Beira, Mozambique, *International Journal of Environment Research and Public Health*, 15(9): 2032.
- Hwida, B., Ahmed, B. A., Ahmed, G., Tagwa, S., Tayseer, E., Ali, N. (2019). Prevalence of malaria and quantification of cytokine levels during infection in East Nile locality, Khartoun State: a cross sectional study.
- Iroezindu, M. O., Agaba, E. I., Okeke, E. N., Daniyam, C. A., Obaseki, D. O., Isa, S. E. and Idoko, J. A. (2012). Prevalence of malaria parasitaemia in adult HIV-infected patients in Jos, North-Central Nigeria. *Nigeria Journal of Medicine*. 21(2): 209-213.
- Jegede, F. E., Oyeyi, T. I., Abdulrahman, S. A. Mbah, H. A., Badru, T., Agbakwuru, C., & Adedokun, O. (2017). Effect of HIV and malaria parasites co-infection on immune-hematological profiles among patients attending anti-retroviral treatment (ART) clinic in Infectious Disease Hospital Kano, Nigeria, *PLoSOne*, 12(3): 1- 17.
- Kamya, M. R., Gasasira, A. F., Achan, J., Mebrahtu, T., Ruel, T., Kekitiinwa, A., *etal.* (2007). Effects of trimethoprim-sulfamethoxazole and insecticide-treated bed nets on malaria among HIV-infected Ugandan children. *AIDS* 21(15): 2059 - 2066.
- Kwenti, T. E (2018). Malaria and HIV Coinfection in Sub-Saharan Africa: Prevalence, Impact and Treatment Strategies. *Research and Reports in Tropical Medicine*. 9: 123-136.
- Nmadu, P. M., Peter, E., Alexandra, P., Koggie, A. Z. and Maikenti, J. I. (2015). The prevalence of malaria in children between the ages of 5 - 15 years visiting Gwarinpa General Hospital, Life-Camp Abuja, Nigeria. *Journal of Health Sciences*, 5(3): 47 - 51.
- Njunda, A. L., Njumkeng, C., Nsagha, S. D., Assob, J. C. N. and Kwenti, T. E. (2016). The prevalence of malaria in people living with HIV in Yaoundé, Cameroon. *Infectious Disease Epidemiology*. 16(1): 964.
- Okonko, I. O., Adejuwon, A. O., Okerentunba, P. O. and Frank- Peterside, N. (2012). *Plasmodiumfalciparum* and HIV-1/2

- coinfection among children presenting at the outpatient clinic of Oni Memorial Children Hospital in Ibadan, Southwestern Nigeria. *Journal of Nature and Science*. **10**(94).
- Onankpa, B. O., Nma, M. J., Tahir, Y. (2017). Malaria parasitemia in HIV-infected children attending antiretroviral therapy clinic in a teaching hospital. *Sahel Medical Journal*. **20**(1): 30-32.
- Ouedraogo, S. M., Sangare, I et al (2015). HIV-Malaria co-infection in the Department of Paediatrics of Centre Hospitalier Universitaire Sourou SANOU (CHUSS). *African Journal of Internal Medicine*. **3**(4): 139 - 145.
- Tagoe, D. N. A. and Boachie, J. (2012). Assessment of the impact of malaria on CD<sub>4</sub><sup>+</sup> T cells and haemoglobin levels of HIV-Malaria co-infected patients. *The Journal of Infection in Developing Countries*. **6**(9): 660-663.
- Tay, S. C., Badu, K., Mensah, A. A., and Gbedema, S. Y. (2015). The prevalence of malaria among HIV seropositive individuals and the impact of the co-infection on their haemoglobin levels. *Annals of Clinical Microbiology and Antimicrobials*, **14**(1): 10 - 17.
- UNAIDS. (2018). Practical Guidelines for intensifying HIV prevention; Towards Universal Access United Nations Programme on HIV/AIDS and World Health Organization. Geneva, Switzerland.
- World Health Organization (2015). Methods Manual: Microscopy for the detection, identification and qualification of Malaria parasites on stained Thick and Thin Blood Film in research settings. TDR/World Health Organization 20, Avenue Appia 1211 Geneva 27, Switzerland.
- World Health Organization. (2017). Malaria in HIV/AIDS Patients. Geneva: WHO. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/malaria>.
- World Health Organization (2019). World Malaria Report 2019. WHO Geneva, Switzerland. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/malaria>.
- World Health Organization. (2020). HIV/AIDS. WHO Geneva, Switzerland. Retrieved from <https://www.who.int/news-room/fact-sheets/detail/hiv-aids#>.